Author pages are created from data sourced from our academic publisher partnerships and public sources.
Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors.
- G. Demetri, M. von Mehren, +18 authors H. Joensuu
- The New England journal of medicine
- 15 August 2002
BACKGROUND Constitutive activation of KIT receptor tyrosine kinase is critical in the pathogenesis of gastrointestinal stromal tumors. Imatinib mesylate, a selective tyrosine kinase inhibitor, has… Expand
Molecular correlates of imatinib resistance in gastrointestinal stromal tumors.
- M. Heinrich, C. Corless, +11 authors J. Fletcher
- Journal of clinical oncology : official journal…
- 10 October 2006
PURPOSE Gastrointestinal stromal tumors (GISTs) commonly harbor oncogenic mutations of the KIT or platelet-derived growth factor alpha (PDGFRA) kinases, which are targets for imatinib. In clinical… Expand
Phase II trial of neoadjuvant/adjuvant imatinib mesylate (IM) for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumor (GIST): early results of RTOG 0132/ACRIN 6665.
BACKGROUND Therapy for gastrointestinal stromal tumors (GIST) has changed significantly with the use of imatinib mesylate (IM). Despite the success of this drug in metastatic GIST, disease… Expand
Insulin-like growth factor 1 receptor is a potential therapeutic target for gastrointestinal stromal tumors
- C. Tarn, L. Rink, +7 authors A. Godwin
- Medicine, Biology
- Proceedings of the National Academy of Sciences
- 17 June 2008
A subset of gastrointestinal stromal tumors (GISTs) lack gain-of-function mutations in c-KIT and PDGFRα. These so-called wild-type (WT) GISTs tend to be less responsive to imatinib-based therapies… Expand
Surgery and Imatinib in the Management of GIST: Emerging Approaches to Adjuvant and Neoadjuvant Therapy
Gastrointestinal stromal tumor (GIST) is a neoplasm of the gastrointestinal tract, mesentery, or omentum that expresses the protein-tyrosine kinase KIT (CD117) and is the most common mesenchymal… Expand
Soft tissue sarcomas of adults: state of the translational science.
- E. Borden, L. Baker, +18 authors M. Brennan
- Medicine, Biology
- Clinical cancer research : an official journal of…
- 1 June 2003
Sarcomas--like leukemias, which are also mesodermal malignancies--carry biological significance disproportionate to their clinical frequency. Identification of mutations and translocations associated… Expand
Phase II Trial of Neoadjuvant/adjuvant Imatinib Mesylate for Advanced Primary and Metastatic/recurrent Operable Gastrointestinal Stromal Tumors: Long-term Follow-up Results of Radiation Therapy…
BackgroundImatinib inhibits the KIT and PDGFR tyrosine kinases, resulting in its notable antitumor activity in gastrointestinal stromal tumor (GIST). We previously reported the early results of a… Expand
Therapeutic effect of imatinib in gastrointestinal stromal tumors: AKT signaling dependent and independent mechanisms.
- C. Tarn, Yuliya V. Skorobogatko, T. Taguchi, B. Eisenberg, M. von Mehren, A. Godwin
- Cancer research
- 15 May 2006
Most gastrointestinal stromal tumors (GISTs) possess a gain-of-function mutation in c-KIT. Imatinib mesylate, a small-molecule inhibitor against several receptor tyrosine kinases, including KIT,… Expand
NCCN Task Force report: optimal management of patients with gastrointestinal stromal tumor (GIST)--expansion and update of NCCN clinical practice guidelines.
- G. Demetri, R. Benjamin, +9 authors M. von Mehren
- Journal of the National Comprehensive Cancer…
- 1 May 2004
NCCN's Sarcoma Clinical Practice Guidelines in Oncology include a subsection regarding treatment recommendations on gastrointestinal stromal tumors (GISTs). GIST is one area of medicine where the… Expand
Tumor Cell-Specific BRCA1 and RASSF1A Hypermethylation in Serum, Plasma, and Peritoneal Fluid from Ovarian Cancer Patients
- Inmaculada Ibañez de Cáceres, C. Battagli, +7 authors P. Cairns
- Cancer Research
- 15 September 2004
Because existing surgical and management methods can consistently cure only early-stage ovarian cancer, novel strategies for early detection are required. Silencing of tumor suppressor genes such as… Expand